Boston, MA -- (SBWIRE) -- 07/25/2014 -- Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer.

View Full Report Details and Table of Contents

TechNavio's analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018.

Covered in this Report

The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy. This report covers the present scenario and the growth prospects of the Global Hormone Replacement Therapy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of the various hormone replacement therapies that are available in the market.

TechNavio's report, the Global Hormone Replacement Therapy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC regions; it also covers the Global Hormone Replacement Therapy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

- Americas
- EMEA
- APAC

Key Vendors

- Actavis plc
- Bayer AG
- Merck & Co. Inc.
- Novartis AG
- Novo Nordisk A/S

Other Prominent Vendors

- Abbott Laboratories Ltd.
- Amgen Inc.
- ANI Pharmaceuticals Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Mylan Laboratories Inc.
- Orion Corp.
- QuatRx Pharmaceuticals Co.
- Teva Pharmaceutical Industries Ltd.
- TherapeuticsMD Inc.

Key Market Driver

- Significant Unmet Need for Hormone Replacement Therapy
- For a full, detailed list, view our report.

Key Market Challenge

- High Cost of Hormone Replacement Therapy
- For a full, detailed list, view our report.

Key Market Trend

- Paradigm Shift Toward Transdermal Systems
- For a full, detailed list, view our report.

Key Questions Answered in this Report

- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: Actavis plc, Bayer AG, Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Abbott Laboratories Ltd., Amgen Inc., ANI Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., MylanLaboratories Inc., Orion Corp., QuatRx Pharmaceuticals Co., Teva Pharmaceutical Industries Ltd., TherapeuticsMD Inc.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
- Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2014
- Hormone-Sensitive Prostate Cancer Global Clinical Trials Review, H1, 2014
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2013
- Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2013
- Partnerships, Licensing, Investments and M&A Deals and Trends for July 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends for June 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends for April 2013 in Pharmaceuticals
- Partnerships, Licensing, Investments and M&A Deals and Trends for February 2014 in Pharmaceuticals